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A phenotype characterised by widespread in-
stability of microsatellite sequences in DNA has
been reported to occur in 10–15% of human colon
cancers [1, 2]. Microsatellites are stretches of re-
peated DNA sequences consisting of mono-, di- or
tri-nucleotide repeats. Mono- and di-nucleotide
microsatellites are either shorter or longer by a few
repeat units in this subset of colon cancers, when
compared to those in the DNA of normal tissues.
Microsatellite instability (MSI) is caused by a de-
fect of the Mismatch Repair (MMR) system, which
has evolved to correct errors of DNA polymerases
[3, 4]. These enzymes are error-prone and, during
DNA replication, they can cause strand misalign-
ments with the formation of loops of extrahelical
bases in the newly synthesised or in the template
strand. These intermediates (i.e., insertion/dele-
tion loops), if not repaired, result in insertions or
deletions of repeat units in the microsatellites of
the progeny DNA. In addition, DNA polymerases
incorporate non-complementary nucleotides into
the newly synthesised DNA strand (i.e., base mis-
matches) with a frequency of approximately one
error per 100 000 nucleotides synthesised. Also
base misincorporations are substrates for the
MMR system, which thus efficiently reduces the
mutation rate from one error every 107 to one error
every 1010 nucleotides. Base mismatches and in-
sertion/deletion loops are recognised by a complex
consisting of the hMSH2 and hMSH6 proteins [5]
(figure 1). Another complex (hMSH2/hMSH3)
(not shown in figure 1), which is less represented
Principles: 10 to 15% of human colon cancers
are associated with an inherited or somatic defect
of the DNA Mismatch Repair (MMR) system,
which has evolved to correct biosynthetic errors
such as nucleotide mis-incorporations or mis-
alignments arising during DNA replication in the
S phase of the cell-cycle. Although expression of
the MMR genes was expected to be cell-cycle de-
pendent, we and others observed that the MMR
proteins hMSH2 and hMLH1 are expressed con-
stitutively in proliferating cells. 
Methods: In this study we extend our observa-
tions to another essential MMR protein, hMSH6.
We used immunohistochemistry to evaluate the
expression pattern of this protein in human colo-
rectal mucosa and tumours, as well as in syn-
chronised HeLa-S3 cells, in which we analysed its
steady-state levels during the cell-cycle.
Results: We show that the immunohistochem-
ical pattern of expression of hMSH6 in normal
colorectal crypts and in colon cancers differs sig-
nificantly from that of the other MMR proteins,
with a much lower percentage of replicating cells
being hMSH6-positive. This implies that hMSH6
could be cell-cycle regulated. In order to test this
hypothesis in a model system, we synchronised
HeLa-S3 cells with mitotic shake-off and found
that the hMSH6 protein was detectable through-
out the cell-cycle, but that its steady-state level in-
creased when cells progressed from G1 to S-phase. 
Discussion: The increase of hMSH6 steady-
state level when cells enter S-phase was expected,
since MMR acts during DNA replication. How-
ever, the overall low level of oscillations of hMSH6
during the cell-cycle in this cellular model appar-
ently does not fit the immunohistochemical phe-
notype. We believe that this discrepancy is due to
the fact that human cell lines proliferate at a much
higher rate than normal and neoplastic colorectal
cells in vivo.
Key words: mismatch repair, hMSH6, cell proli-
feration, colon cancer
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Introduction
in human cells, plays a back-up role only in the
recognition of loops, since it does not recognise
base mismatches [6, 7]. After recognition, a second
heterodimeric complex, hMLH1/hPMS2, is re-
cruited. Although the function of this latter com-
plex is still unknown, it has been suggested that it
acts as a molecular matchmaker between the mis-
match recognition complex and a series of proteins
(helicases, exonucleases, etc.) necessary to excise
the tract of the newly synthesised strand carrying
the aberrantly paired bases (figure 1, see legend for
details) [4].
Of particular interest is a biochemical property
of the three above-mentioned heterodimers: one
partner is stable also in monomeric form (hMSH2
in the hMSH2/hMSH6 and hMSH2/hMSH3 het-
erodimers, and hMLH1 in the hMLH1/hPMS2
heterodimer), whereas hMSH6, hMSH3 and
hPMS2 are unstable as monomers [7, 8]. Most
human MMR-deficient colon cancers have genetic
or epigenetic alterations of the hMSH2 and
hMLH1 genes (http://www.nfdh.nl/database/
mdbchoice.htm) [2]. In particular, 2–5% of colon
cancers are associated with a germ-line mutation
(inherited in all cells of the body) in one of these
two genes in members of Hereditary Nonpolypo-
sis Colon Cancer (HNPCC) families, and 8–12%
of colon cancers are associated with promoter
hypermethylation of both hMLH1 alleles at the
somatic level (in the colonocytes) [2]. As a conse-
quence, hMSH6 is degraded in hMSH2-negative
tumours, and hPMS2 is degraded in hMLH1-neg-
ative tumours. The functional significance of this
phenomenon is still unknown. One possibility
could be that the stable partner is involved in other
processes other than MMR, and the degradation
of the unstable partner is necessary for the former
to function in these pathways, alone or in combi-
nation with other proteins. In fact, yeast homologs
of hMSH2, hMSH3, hMLH1 and hPMS2 have
also been found to be involved in DNA recombi-
nation [9, 10]. 
In contrast, the only role found to date for
hMSH6 is in MMR. MMR occurs during DNA
replication in S phase, thus we hypothesised that
an assembled hMSH2/hMSH6 complex is neces-
sary in this phase of the cell-cycle. We and others
[11, 12] previously found that the steady-state lev-
els of hMSH2 are very low in cell lysates of rest-
ing cells, but that a considerable increase of its lev-
els is observed when cells enter the cell-cycle.
However, only minor oscillations of the steady-
state levels of hMSH2 are observed during the 
cell-cycle, as is usually observed with products of
housekeeping genes. We set out to extend our
observations to the expression and degradation
patterns of hMSH6 during the cell-cycle. 
Due to the intrinsic instability of hMSH6 in
monomeric form, we supposed that higher oscilla-
tions of its steady-state levels could be found.
hMSH6 is essential in MMR because it is the ac-
tual mismatch-recognition protein of the hMSH2/
hMSH6 complex [5, 13, 14]. Its specificity for the
recognition of base mismatches and its redundancy
with hMSH3 in the repair of loops explains why
human cell lines with mutations in hMSH6 show
only a very low degree of MSI, mainly in mononu-
cleotide repeats [1]. Thus, in addition to colon
cancers with a high degree of MSI, MMR-defi-
cient tumours with a high mutation rate but with-
out or with only low-degree MSI could be found.
Recently, familial aggregations of colon cancer
with germ-line mutations in hMSH6 have been
described [15–18], and hypermethylation of the
hMSH6 promoter has also been demonstrated in a
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Figure 1
Putative model of
human MMR. (1) The
mismatched “T”,
introduced into the
newly synthesised
strand by the repli-
cation complex, is
recognised by the
hMSH2/hMSH6 het-
erodimer. (2) ATP
drives the bi-direc-
tional threading of
DNA, which makes a
loop and (3) recruits
other essential mem-
bers of the MMR
complex, such as the
hMLH1/hPMS2 het-
erodimer and PCNA.
(4) Exonucleolytic
degradation of the 
T-containing strand 
is initiated by an as
yet unidentified heli-
case(s) and exonucle-
ase(s). (5) DNA syn-
thesis is re-initiated
by the replication
complex and a “C” 
is normally paired
with “G”. 
The recognition com-
plex hMSH2/hMSH3,
not included in this
figure, does not
recognise base mis-
matches, but only
insertion/deletion
loops (see Introduc-
tion). However, the
repair process down-
stream of the DNA
binding is essentially
the same as that de-
scribed in this figure
for base mismatches.
cellular model [19]. Thus, it is crucial to charac-
terise the expression and degradation patterns of
hMSH6, because abnormalities of these patterns
could result from missense mutations or epigenetic
modifications of this gene. We report here the
results obtained by using both an immunohisto-
chemical approach in human colorectal samples
and a cellular model suitable for cell-cycle analy-
sis.
S W I S S  M E D  W K LY 2 0 0 2 ; 1 3 2 : 5 7 – 6 3 ·  w w w. s m w. c h 59
Methods
Immunohistochemistry
Normal and tumour colorectal samples were ob-
tained from the department of Pathology of Triemli
hospital in Zürich involved in a national screening pro-
gram aimed at the identification of MMR-deficient colon
cancers (www.imr.unizh.ch/research/jiricny/HNPCC/
hnpcc.html). 4 µm serial sections from paraffin blocks
were mounted on silanised slides, deparaffinised and re-
hydrated. Antigen retrieval was accomplished by heating
the sections in a pressure cooker at 120 °C for 2 min in 10
mM citrate-buffered solution (pH 6.0). DAKO peroxidase
blocking reagent and goat serum were sequentially used
to suppress non-specific staining due to endogenous
peroxidase activity and non-specific binding of antibodies,
respectively. Incubation with primary monoclonal anti-
bodies was performed as follows: anti-hMSH2: 24 hours
at 4 °C with Ab NA26 (Oncogene Research), 1 µg/ml;
anti-hMSH6: 2 hours at RT with Ab G70220 (Transduc-
tion Laboratories), 4 µg/ml; anti-hMLH1: 1 hour at RT
with Ab 13271A (PharMingen), 1.2 µg/ml; anti-hPMS2:
24 hours at 4 °C with Ab 65861A (PharMingen), 3 µg/ml.
After washing, anti-mouse secondary antibodies conju-
gated to peroxidase labelled polymer (DAKO EnVision+
kit) were applied for 30 min at RT, and the peroxidase ac-
tivity was developed by incubation with 3,3’diaminoben-
zidine (DAB) chromogen solution (DAKO). The sections
were then counterstained slightly with haematoxylin.
Cell synchronisation of HeLa-S3 cells by mitotic
detachment
Synchronous cultures of HeLa-S3 (cultured in Is-
cove’s modified Dulbecco’s medium supplemented with
10% FBS and 2 mM L-glutamine, Life Technologies)
were obtained using a manual system for partitioning of
detached cells [20]. Cells were plated into 150 mm dishes
at a density of 1.5104/cm2. When they were exponen-
tially growing, detached rounded cells were removed and
discarded, and fresh pre-warmed (37 °C) serum-supple-
mented medium was added. Newly-detached cells were
collected from the cell culture dishes every 1.5 h, replated,
and incubated for various lengths of time from 0 to 15 h
(5 time points). An aliquot of cells at each time point was
fixed for cell-cycle analysis, whereas another aliquot was
harvested for Western blot analysis.
Cell-cycle analysis
1106 cells per time point were washed with PBS and
fixed in ice-cold 70% ethanol. The cells were treated with
200 U/ml RNase A and stained with 20 µg/ml propidium
iodide. Cell-cycle analysis was performed using a Becton
Dickinson FACscan flow cytometer and Cell Quest soft-
ware.
Preparation of total protein extracts
8106 cells were washed twice with PBS, collected
and dissolved in 180 µl of ice-cold lysis buffer (50 mM 
Tris-Cl, pH 8.0, 350 mM NaCl, 1% NP40, 1 mM EDTA,
1 mM phenylmethylsulphonyl fluoride, 2 µg/ml aprotinin, 
0.7 µg/ml pepstatin, and 1 EDTA-free Complete –
Boehringer). After 10–20 minutes incubation on ice, the
completion of the cell lysis was verified under the micro-
scope with trypan blue staining. The lysate was cen-
trifuged in an Eppendorf microfuge for 5 minutes at
12 000 xg and the supernatant was collected, snap frozen
in small aliquots in liquid nitrogen and stored at –80 °C.
Gel electrophoresis and Western blot analysis
50 µg of total proteins from each sample were loaded
on a 7.5% SDS-PAGE and electroblotted onto poly
(vinylidene difluoride) membranes. The blots were first
blocked in TBST (0.1% Tween 20 in Tris-buffered saline)
containing 5% non-fat dry milk for 1 h at 37 °C, and then
incubated with the respective primary monoclonal anti-
bodies for 1 h at room temperature. The primary antibody
concentrations were: anti-hMSH6 (no. G70220–050,
Transduction Laboratories), 0.125 µg/ml; anti-hMSH2
(no. NA26, Oncogene Science), 0.65 µg/ml; anti-TFIIH
p89 (no. sc-293, Santa Cruz), 0.04 µg/ml; anti-cyclin E
(no. MS-870–P, NeoMarkers), 0.2 µg/ml, and cyclin B1
(no. 05–373, Upstate biotechnology), 1 µg/ml. After wash-
ing with TBST, the blots were incubated with horserad-
ish peroxidase conjugated sheep anti-mouse Ig (no. NXA
931, Amersham Pharmacia, diluted 1:5000) for 1 h at room
temperature. The protein-antibody complexes were de-
tected with the enhanced chemiluminescence system
(Amersham Pharmacia). The pre-stained molecular
weight marker (no. 161–0318, BIO-RAD) was loaded
alongside the samples on each gel. The intensity of the
bands was quantified relative to TFIIH p89, using the Im-
ageQuant software of the Computing Densitometer
(Molecular Dynamics).
Statistical analysis
Nuclei stained and unstained with anti hMSH2 or
anti hMSH6 antibodies were counted in 22 colorectal
crypts and 18 tumours. Multiple logistic regression was
used to evaluate the odds ratio associated with being
stained when treated with anti hMSH2 versus anti
hMSH6 antibodies after adjusting for the confounding ef-
fects of the differences between patients and the different
number of nuclei in each sample. To evaluate whether the
expression of hMSH6 significantly increased from time
points 3 h to 9 h when compared with the changes of the
housekeeping gene TFIIH p89 at the same time points,
the natural logarithms of the expression were compared
using the t test (data obtained from three independent ex-
periments). The use of logarithms enabled normalisation
of the distribution and comparison by ratios rather than
absolute differences.
Immunohistochemistry for MMR proteins
has been performed in our laboratory for the past
3 years as a tool to screen colorectal cancers for
MMR deficiency. Four proteins were routinely
tested in these tumours: hMSH2, hMSH6,
hMLH1 and hPMS2. As expected, MMR proteins
were expressed in proliferating cells, i.e., in the
lower two thirds of the normal colorectal crypts
and in most of the tumour cells (figure 2, panels A
and B; hMLH1 and hPMS2, not shown, have a
staining pattern similar to that of hMSH2). How-
ever, we found a consistent difference in the ex-
pression pattern between hMSH6 and the other
three proteins. In the normal colorectal crypt,
most of the nuclei of proliferating cells were posi-
tive for hMSH2, hMLH1 and hPMS2, whereas
hMSH6 expression was limited to only a few of the
cells of the proliferative compartment (figure 2,
panel A). Also in neoplastic colorectal samples
(figure 2, panel B), the expression of hMSH6 was
more “selective” among proliferating cells, dis-
playing an interspersed pattern. In contrast, the
other three MMR proteins were expressed abun-
dantly in most of the tumour cells. Multiple logis-
tic regression analysis showed that the difference
in number of nuclei stained with anti hMSH6 or
anti hMSH2 antibodies was statistical significant
(p <0.00001), both in colorectal crypts and in tu-
mours.
This staining pattern prompted us to investi-
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Results
Figure 2
Imunohistochemical expression patterns of hMSH2 and hMSH6 in colorectal mucosa
and tumours. 
A) normal mucosa: MMR proteins are expressed in the proliferative compartment 
of the colorectal crypts (lower 2/3) where most of the nuclei are positive for hMSH2,
whereas hMSH6 expression is confined to only some of the cells of this compartment. 
B) adenomatous region of a colon cancer: also in these lesions, the pattern of expres-
sion of hMSH6 is “interspersed”, whereas hMSH2 is expressed in most of the tumour
cells. 
C) MMR-deficient colon carcinoma: this tumour was excised from a member of a
HNPCC family carrying a germ-line mutation in hMSH2. 
Usually, a second alteration occurs in the wild-type allele of hMSH2 in the tumour and
hMSH2 is not expressed at all. Consequently, hMSH6 is degraded (see Introduction)
and the same tumour is also negative for this latter protein. Some non-neoplastic
cells in the lamina propria are positive for hMSH2 and hMSH6 as expected, and the
other MMR proteins are normally expressed in this tumour as shown for hMLH1 in the
superimposed image in C.
Figure 3
Flow cytometry analysis of
HeLa-S3 cells synchro-
nised by mitotic shake-off
(see methods). Compare
the DNA content of asyn-
chronous cells with that of
cells at different time
points after mitosis. 0 h
(suspension cells har-
vested and fixed): a por-
tion had already passed to
G1, presumably during the
harvesting period; 
3 h after re-plating 
of suspension cells: most
of the cells were in G1; 
9 h: cells were traversing 
S phase; 12 h: they
reached G2; 15 h: a second
G1 phase was reached.
gate if hMSH6 steady state levels could be regu-
lated during the cell-cycle in an in vitro cellular
model. We chose HeLa-S3 cells because these cells
have a particular behaviour in tissue culture: they
detach in mitosis. This phenotype allowed us to
synchronise them with a method called mitotic
shake-off [20] and to avoid perturbations in cell
metabolism introduced by synchronising agents.
Mitotic cells in suspension were harvested at dif-
ferent time points and re-plated in new flasks for
the time lag needed to reach different cell-cycle
phases after cell division. Re-plated cells were har-
vested after 3, 9, 12 and 15 h and their progression
throughout the cell-cycle was monitored by flow
cytometry (figure 3). Suspension cells were also
harvested and immediately fixed for flow cytome-
try: as shown in figure 3, most were in the G2/M
peak, even though a portion had already passed 
to G1 (compare with the flow cytometric pattern
of asynchronous cells), presumably during the
harvesting period. At 3 h, most of the cells were in
G1, as expected. They passed through S phase at
9 h and reached G2 phase at 12 h. At 15 h a sec-
ond G1 phase was reached.
Proteins were extracted at these time points
and Western blots for MMR proteins were per-
formed. The steady state levels of cyclin E and 
B1 were also analysed to verify the progression
through the cell-cycle. The expression of the
housekeeping protein TFIIH p89 was used as an
internal control. Dramatic increases of cyclin E 
in S phase and cyclin B1 in G2/M were observed
(figure 4) confirming the good degree of cell-
cycle synchronisation. The steady-state levels of
hMSH2, hMSH6, hMSH3, hMLH1 and hPMS2
did not show dramatic variations during the cell-
cycle in proliferating cells (data shown for hMSH6
and hMSH2 in figure 4), confirming the data al-
ready published by us and other groups (see Intro-
duction). However, a 25% increase of hMSH6
steady-state levels was observed when HeLa-S3
cells entered S phase (figure 4, compare 3 h vs 9 h).
This increase, although of low degree, was consis-
tent in different experiments (three of which are
shown in figure 4) and was statistical significant 
(p = 0.01). 
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Figure 4
Western blot analysis
of proteins extracted
from HeLa-S3 cells at
different time points
after mitosis. The
steady-state levels of
hMSH6 and hMSH2
are high in every
phase of the cell-
cycle, although a
consistent increase
(25%, p = 0.01) of
hMSH6 was always
observed when cells
entered S phase
(compare 3 h vs 9 h;
three of the several
blots performed are
shown here). Data
from three independ-
ent experiments were
compared with the
steady-state level of
the housekeeping
protein TFIIH p89.
Cyclin E and B1 ex-
pression was used as
a control of cell syn-
chronisation. Extracts
from HeLa and LoVo
cell lines were used
as positive and nega-
tive controls of
hMSH2/hMSH6
expression, respec-
tively.
Discussion
As already mentioned in the Introduction,
hMSH6 is an essential protein in DNA mismatch
repair because it is the actual molecule that recog-
nises the mismatched bases, even though this
function is active only when hMSH6 is het-
erodimerised with hMSH2 [5, 21]. In addition,
hMSH6 is >10 times more abundant than hMSH3
in human cells [6] suggesting that also the repair
of insertion/deletion loops is primarily performed
by hMSH2/hMSH6. However, the hMSH2/
hMSH3 complex is efficient in repairing loops in
hMSH6–/– cells [7] which, for this reason, show a
high mutation rate but do not display a high de-
gree of MSI. In our opinion, this biochemical find-
ing could explain why most of the MMR-deficient
tumours in the colon (and in other organs where
MMR alterations were investigated, such as in the
endometrium) have been mostly associated with
mutations in hMSH2 and hMLH1. The fact that
MSI has been extensively used to screen for MMR
deficiency in tumours could have underestimated
MMR-deficient tumours without MSI. However,
familial aggregations of colorectal and endome-
trial cancers associated with germ-line mutations
in hMSH6 have been frequently described in the
recent years [15–18], and the possibility thus exists
that a subset of sporadic (i.e., non-familial) cancers
arises due to a high mutation rate caused by genetic
or epigenetic alterations of hMSH6. We are at
present analysing, in a prospective study, conse-
cutive colon cancers from several hospitals in
Switzerland for alterations in MMR genes using
different techniques in order to evaluate the real
incidence and the type of hMSH6 alterations.
In this study, we have used immunohisto-
chemistry to confirm that the expression of MMR
proteins is strictly associated with cell prolifera-
tion. Four of the MMR proteins we have studied
were indeed expressed in the nuclei of cells lining
the proliferating zone of the normal colorectal
crypt, ie, its lower two thirds. Their expression was
lost in the upper third of the crypt, where cells 
are non-proliferating and differentiated. The ex-
pression level was high in most of the cells in the
proliferative compartment, suggesting that MMR
proteins are expressed in all phases of the cell-
cycle. However, hMSH6 showed a different pat-
tern: only a portion of the cells in the proliferative
compartment were strongly positive, whereas
other cells were either only weakly positive or neg-
ative. The interspersed staining pattern of hMSH6
was also apparent in colorectal adenomas and car-
cinomas, and we found similar expression patterns
in the skin and in melanomas (S. D’Atri et al., Jour-
nal of Investigative Dermatology, in press). This
pattern suggests that hMSH6 expression and/or
degradation are more tightly regulated in vivo than
those of the other MMR proteins. We plan to in-
vestigate this phenotype in more detail with fresh
colorectal samples and immunofluorescence in
order to identify the cell-cycle phase(s) in which
hMSH6 is expressed. Biochemical studies are also
in progress to study the kinetics of MMR protein
degradation in human cells.
However, we suppose that the cells with higher
expression of hMSH6 in vivo might be in the S
phase of the cell-cycle, as is expected for proteins
that function during DNA replication. This hypo-
thesis is also supported by the experiments re-
ported in this study using HeLa-S3 cultures, which
allowed us to isolate cells in different cell-cycle
phases in the absence of synchronising agents. In
this system, we consistently found an increase of
the steady-state level of hMSH6 when the cells 
entered S phase. In these cells however, hMSH6
was also expressed in every phase of the cell-cycle,
as demonstrated for the other MMR proteins [11,
12]. The proliferative rate of HeLa-S3 cells in vitro
is very high, with a doubling time of 15 h. On the
contrary, the rate of cell proliferation in the nor-
mal colorectal mucosa is lower, since the cell-cycle
duration of colorectal epithelial cells has been es-
timated to be between 30 and 40 h [22]. During the
transit throughout the cell-cycle phases, colono-
cytes also migrate from the bottom of the crypts to
the lumen with a cellular turnover time of 4–8 days
[22]. The rate of cell proliferation in colorectal
cancers is highly variable, depending mainly on the
stage and vascularisation of the tumour; however,
colon cancer cells often have a longer cell genera-
tion time than normal colonocytes [22]. Thus, the
oscillation of the steady-state level of hMSH6 sug-
gested by the immunohistochemical pattern could
be less pronounced in cells, such as HeLa-S3,
which proliferate quickly in vitro, especially in the
eventuality that the degradation of hMSH6 is slow.
One explanation of the tighter regulation of
hMSH6 levels compared to those of hMSH2 is
that in vitro and in vivo (in yeast) studies [9, 10] have
shown the involvement of the latter protein in
other pathways of DNA metabolism, in particular
in DNA recombination and in the repair of large
single-strand DNA loops. Yeast homologues of
hMLH1 and hPMS2 were also found to be in-
volved in recombination [9, 10]. We found that the
steady-state levels of these two latter proteins were
also similar throughout the cell-cycle ([11, 12], and
data not shown) and the immunohistochemical
pattern of hMLH1 and hPMS2, similar to that of
hMSH2, suggests that they are probably needed in
all phases of the cell-cycle. The competition be-
tween hMSH6 and hMSH3 for hMSH2 suggests
that hMSH6 may be degraded in order to make
hMSH2 available for hMSH3 to function in other
pathways. We did not find significant variations of
hMSH3 steady-state levels during the cell-cycle
(data not shown) and the expression pattern of this
protein in colon samples was not performed due 
to the unavailability of reliable anti-hMSH3 anti-
bodies for immunohistochemistry.
At present, different morphological and bio-
chemical approaches are exploited in our labora-
tories to better understand the regulation of
hMSH6 expression. Our effort to evaluate the ex-
pression/degradation pattern of the hMSH6 pro-
tein is crucial to understand the mechanism of dys-
function of the MMR system and, with regard to
its interaction with hMSH2, of other pathways of
DNA metabolism. We believe that these studies
will elucidate the mechanisms of abnormal DNA
metabolism in a subset of human tumours.
We thank Eva Niederer (Zentrallabor für Zellsor-
tierung ETH/UNI, Zürich) for help with the flow cyto-
metric analysis and Peter Binz for graphic contributions. 
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